Last week, we examined ways the latest drug pricing proposal will undermine patient access to medicines, American medical innovation and our health care system as a whole. But there is another consequence that we can’t leave out: the impact this proposal will have on the biopharmaceutical industry’s contributions to American jobs and the economy.